Market Newsdesk

NEW YORK, Sept. 27, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients. Specifically, that insiders repeatedly touted the potential growth for the Zio AT as an innovative product that had only just begun to penetrate the market for real-time monitoring, which investors looked upon favorably given the premium selling price associated with devices approved for high-risk patients. As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices at relevant times.

If you currently own IRTC and purchased prior to July 25, 2022 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814

SAN FRANCISCO, Sept. 26, 2026 (GLOBE NEWSWIRE) — National shareholder rights law firm Hagens Berman encourages investors in DNOW Inc. (NYSE: DNOW) who suffered substantial losses submit your losses now. A securities class action lawsuit has been filed regarding potential violations of federal securities laws involving DNOW’s acquisition of MRC Global Inc. and undisclosed enterprise software integration failures in the merger proxy materials.

• Lead Plaintiff Deadline: Oct. 2, 2026
• Defined Investor Class and Record Date: Shareholders who held DNOW common stock as of the August 5, 2025 record date and were thus entitled to vote at DNOW’s September 9, 2025 special meeting on the merger of DNOW and MRC Global

Investors with significant losses are urged to contact the firm to review their options:

• Visit:
  www.hbsslaw.com/dnow
• Emai:
  [email protected]
• 
  Call Direct: 844-916-0895
  
• 
  Video:
  
  
  
  youtu.be/aKY_E92X2Us
  
  
• Blog:
  
  www.hbsslaw.com/blog/dnow-the-synergy-charade
  
  

Allegedly Misleading Proxy Materials:

The suit alleges that the Proxy Materials misrepresented and omitted to disclose challenges posed with DNOW’s merger with MRC Global Inc. as a result of material issues affecting MRC Global’s new ERP system.

The Truth Allegedly Emerges

• November 5, 2025 — Reassurances Before Acquisition: The complaint alleges that on DNOW’s Q3 2025 earnings call—the day before closing the merger—management assured investors that MRC Global had implemented a “state-of-the-art” Enterprise Resource Planning (ERP) system that promised “improved inventory management, order processing efficiency, and supply chain optimization.” DNOW allegedly minimized integration risks, reassuring the market that MRC’s past software glitches were merely an “isolated, one-time event.”
• February 20, 2026 — The Disclosures: DNOW reported its Q4 and full-year 2025 financial results, revealing that MRC revenues had sharply declined due to “persistent ERP challenges” and acknowledging that MRC’s software implementation was, in fact, an “obstacle.”
• Operational Flaws & Guidance Delay: Management conceded that flawed software design architecture caused severe operational slowdowns, impeded customer service, and required substantial unexpected capital expenditure to remediate. Consequently, DNOW was forced to delay its sequential and full-year 2026 financial guidance.
• Market Impact: On this news, DNOW stock crashed 19% in a single trading session.

Statement from Hagens Berman Partner Reed Kathrein

“We are focused on whether the Proxy Materials downplayed ERP integration failures at MRC Global allowing management to push the deal through, as the complaint alleges,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the claims in the pending suit.

What DNOW Investors & Whistleblowers Can Do

• DNOW Investors: If you purchased DNOW common stock and sustained significant losses, you may be eligible to take an active role in the class action. The court-appointed lead plaintiff deadline is October 2, 2026.Submit your loss details here.

• Whistleblowers: Persons with non-public information regarding DNOW should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

A video accompanying this press release is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/9a6f797d-9fae-49ea-9337-f98f57e5ea8f

SAN FRANCISCO, Sept. 26, 2026 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP alerts investors in Pentair plc (NYSE: PNR) that a securities fraud class action lawsuit filed against the company has been expanded to cover an earlier class period. Investors who suffered substantial losses are urged to submit their losses now.

CASE DETAILS

Expanded Class Period: March 11, 2025 – July 14, 2026 (Previously April 28, 2026 – July 14, 2026)
Lead Plaintiff Deadline: Oct. 2, 2026
Contact Hagens Berman: Visit www.hbsslaw.com/pnr, email [email protected], or call (844) 916-0895
Blog: www.hbsslaw.com/blog/the-undisclosed-bottleneck-pentair-plc-pnr

ALLEGED MISCONDUCT & EXPANDED CLASS PERIOD

The new class action lawsuit alleges that beginning on March 11, 2025, Pentair plc and certain of its top executives made a series of materially false and misleading statements and omitted critical adverse operational information regarding Pentair’s financial health, channel inventory, and internal controls.

Specifically, the lawsuit alleges Defendants failed to disclose that:

1. Pentair was experiencing severe, undisclosed channel inventory destocking—particularly within its core Pool segment.
2. The company engaged in unsustainable channel-loading and sales practices with distributors to artificially inflate short-term financial metrics.
3. As a result, Pentair’s positive statements regarding its business, full-year financial guidance, and operating income lacked a reasonable basis.

THE DISCLOSURE & MARKET REACTION

The complaint alleges that the artificial inflation in Pentair shares came to an abrupt end on July 14, 2026, after the market closed, when Pentair shocked investors by pre-announcing preliminary second-quarter 2026 financial results that fell substantially below consensus estimates.

The disclosures revealed severe operational headwinds:

• Massive Revenue Miss: Sales were expected to be approximately $930 million—a drastic miss against prior forecasts of $1.14 billion. The company disclosed that inventory destocking in the Pool channel negatively impacted Pool segment sales by approximately $170 million and income by approximately $105 million.
• Full-Year Guidance Slashed: Pentair dramatically cut its full-year 2026 outlook, reversing earlier projections. Full-year sales were projected to be down approximately 4% to 7%, compared to prior guidance of up 2% to 4% growth.
• Abrupt CFO Departure: Compounding the shock, Pentair announced the immediate departure of its Chief Financial Officer, Nicholas Brazis, after serving in the role for only four months, raising questions regarding internal controls and financial reporting.

Following these disclosures, Pentair’s stock price plummeted 15% in a single session—losing $11.35 per share to close at $64.33 on unusually heavy trading volume on July 15, 2026.

“We are closely examining the timing of these disclosures, the sudden departure of the CFO after only four months, and the severe impact of channel destocking on Pentair’s financial health,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the alleged claims.

What Affected PNR Investors Should Do

If you purchased or acquired Pentair common stock between March 11, 2025, and July 14, 2026, and suffered significant financial losses, you have until October 2, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/pnr, call Reed Kathrein at 844-916-0895, or email [email protected].

If you’d like more information and answers to other frequently asked questions about the Pentair case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Pentair should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/619cda35-e749-4277-8422-5553068c6f78

SAN FRANCISCO, Sept. 26, 2026 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP—a national plaintiffs’ rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration’s (FDA) recent decision to extend the review period for Capricor’s Biologics License Application (BLA), underscoring the ongoing regulatory and disclosure scrutiny surrounding the company.

Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now.

FDA Extends BLA Review Following Post-AdCom Submissions

On Aug. 24, Capricor announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for Capricor’s lead investigational cell therapy, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD), moving the decision date from August 22, 2026, to November 22, 2026.

The agency classified Capricor’s recent submission—which follows a turbulent July 2026 Advisory Committee meeting and includes 24-month open-label extension data from the Phase 3 HOPE-3 study alongside a request to pivot toward a refined indication focused solely on upper limb function—as a major amendment.

Securities Class Action Details & Overview

• Class Period: Dec. 17, 2025 – July 26, 2026
• Lead Plaintiff Deadline: Sept. 28, 2026
• Visit:
  www.hbsslaw.com/capr
• Contact the Firm Now:
  [email protected] / 844-916-0895
• Video:
  youtu.be/-lnVTKgV6as
• Blog:
  www.hbsslaw.com/blog/when-the-statistical-analysis-plan-gets-a-24-hour-makeover-capricor-capr

Core Allegations and Background

• Material Misleading Statements Regarding Clinical Trial Data and SAP Changes: The lawsuit alleges that Capricor and certain executives made materially false and misleading statements regarding the clinical trial data and regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, defendants allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).

• The HOPE-3 Trial Breakthrough and Subsequent Capital Raise: On December 3, 2025 Capricor announced “Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy.” The company’s CEO said “HOPE-3 delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function.” Driven by these claims, Capricor’s share price surged 370% to close up $23.60 on December 3, 2025. The following day, the company launched a public stock offering of approximately 6 million shares priced at $25 per share.

• FDA Briefing Document Reveals SAP Changes and Triggers 64% Stock Collapse: Capricor’s public assurances unraveled on July 27, 2026, when the FDA published briefing documents ahead of an Advisory Committee meeting. The documents revealed that Capricor made unagreed-upon post-hoc modifications to its pre-specified Statistical Analysis Plan (SAP). The FDA stated that the HOPE-3 study “did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months.” Capricor shares crashed roughly 64% in a single day to close at $7.00. An Advisory Committee subsequently voted 9–3 against the efficacy of the drug, compounding investor losses.

Hagens Berman’s Investigation

“We’re focused on investors’ losses and uncovering the full scope of how management characterized these trial endpoints and undisclosed modification,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation on the claims alleged in the pending suit.

What Affected CAPR Investors Should Do

If you purchased or acquired Capricor securities between December 17, 2025, and July 26, 2026, and suffered significant financial losses, you have until September 28, 2026, to ask the court to appoint you as lead plaintiff. You do not need to seek lead plaintiff status to share in any potential recovery.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/capr, call Reed Kathrein at 844-916-0895, or email [email protected].

If you’d like more information and answers to frequently asked questions about the Capricor case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Capricor should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

A video accompanying this press release is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/6f678829-075c-453f-81b2-9a00f7f41a2f

NEW YORK, Sept. 26, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Papa
John’s International, Inc. (“Papa John’s” or the “Company”) (NASDAQ: PZZA) common stock between August 7, 2025 and August 5, 2026, inclusive (the “Class Period”).

Investors who purchased Papa John’s shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for November 2, 2026.

PLEASE CLICK HERE TO SUBMIT CONTACT AND TRADE INFORMATION

The filed complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failing to disclose material adverse facts to investors, including that:

• Defendants created the false impression that they possessed reliable information pertaining to the effectiveness and ongoing impact of the Company’s strategic transformation as well as their resulting projected growth outlook for the North American region;
• Defendants also minimized the risk of cautious consumer sentiment, competition, promotional seasonality, and more general macroeconomic fluctuation;
• In truth, Papa Johns’ strategic transformation was taking considerably longer than the projections had suggested and the Company was simply ill equipped to “meet the consumer where they’re at;” and
• As a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

On August 6, 2026, Papa Johns issued its second quarter 2026 financial results, reporting an 8.3% decline in North American comparable sales. The Company also reduced its fiscal 2026 outlook, expecting “global system-wide sales to decline between 2% and 4% compared to last year and adjusted EBITDA between $180 million to $190 million,” and suspended its quarterly dividend. During the related conference call, CEO Todd Allan Penegor stated that “it’s clear that our transformation is taking longer than expected” and “we must execute better and move faster.”

On this news, Papa Johns’ stock price fell $5.11 or 17.18%, to close at $24.64 per share on August 6, 2026,

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website:
Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Singapore, Sept. 26, 2026 (GLOBE NEWSWIRE) — Platinum Analytics Cayman Limited (the “Company” or “PLTS”), a software developer specializing in the provision of FX trading software development solutions, data analytics solutions and technology development solutions to financial institutions with a strategic focus on serving Asia and other emergent markets, today announced that on September 21, 2026, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Nasdaq Hearings Panel (the “Panel”) had denied the Company’s request to reinstate trading on Nasdaq and determined to delist the Company’s securities (the “Panel Decision”). 

As previously disclosed, the Company received a Staff Delisting Determination from Nasdaq’s Listing Qualifications Department pursuant to Nasdaq Listing Rule IM-5101-4. The Company appealed that determination by requesting a hearing before the Panel pursuant to Nasdaq Listing Rule 5815. Following a hearing held on August 18, 2026, the Panel affirmed Nasdaq Staff’s determination to delist the Company’s securities. 

The Panel based its decision principally on trading activity indicative of potential manipulation and the Company’s failure to demonstrate sufficient liquidity to support a fair and orderly market. However, the Panel was unpersuaded by Staff’s arguments concerning the Company’s professional advisors, finding that their prior involvement with other companies that had experienced trading halts, anomalous trading or FINRA enforcement matters did not, standing alone, constitute valid grounds for delisting. The Panel also found that the residence of the Company’s chief executive officer in Singapore did not support delisting. Trading in the Company’s securities was suspended at the opening of trading on September 23, 2026. 

The Company intends to request that the Nasdaq Listing and Hearing Review Council review the Panel Decision pursuant to Nasdaq Listing Rule 5820. A request for review by the Listing and Hearing Review Council will not stay the suspension of trading in, or the delisting of, the Company’s securities. There can be no assurance that the Company’s request for review will be successful or that trading in the Company’s securities will resume on Nasdaq. 

About Platinum Analytics Cayman Limited 

Established in 2017 in Singapore, Platinum Analytics Cayman Limited, through its wholly-owned Singapore subsidiary, Platinum Analytics Singapore Pte. Ltd., develops FX trading software, data analytics, and technology solutions for financial institutions, focusing on Asia and other emergent markets. Supported by the Monetary Authority of Singapore (MAS), it addresses rapid growth in currency trade volumes, complex cross-border transactions, and emerging market volatility. 

The Company operates the Platinum ECN spot FX trading platform for institutional and enterprise clients. Its products – Platinum AI, Platinum ECN, and Platinum Smart Trade – deliver scalable, flexible, AI-driven, low-latency trading and analytics. For more information, please visit: www.platinumanalytics.net. 

Forward-Looking Statement 

This press release contains forward-looking statements that involve risks and uncertainties. The risks and uncertainties involved include the Company’s ability to regain compliance with Nasdaq’s rules for continued listing, market conditions, and other risks detailed from time to time in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current expectations and assumptions and speak only as of the date of this press release. The Company does not intend to revise or update any forward-looking statement in this press release as a result of new information, future events or otherwise, except as required by law.  

For more information, please contact: 

International Elite Capital  

Annabelle Zhang  

Email: [email protected]  

646-866-7928